| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
Recruitment opened |
| 2026-06-12 | NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
Trial sites expanded: 0 -> 41 locations |
| 2026-06-12 | NCT05111574 Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-09 | NCT07405164 Extension Study for Participants in Studies That Include Belzutifan… |
Trial sites expanded: 15 -> 20 locations |
| 2026-06-06 | NCT05168618 Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant… |
date change Primary completion pushed: 2026-05 -> 2026-07 |
| 2026-06-03 | NCT07011719 Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With… |
Trial sites expanded: 97 -> 118 locations |
| 2026-05-27 | NCT07293351 A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in… |
Trial arms changed: 10 -> 9 |
| 2026-05-16 | NCT06475989 Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer |
Trial sites expanded: 112 -> 301 locations |
| 2026-05-15 | NCT07011719 Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With… |
Trial sites expanded: 44 -> 97 locations |
| 2026-05-15 | NCT05425004 Cabozantinib for Patients With Recurrent or Progressive Meningioma |
date change Primary completion pushed: 2026-10 -> 2026-12 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Refractory Differentiated Thyroid Gland Carcinoma | Recruiting |
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With… | Metastatic Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer… | Renal Cell Carcinoma | Recruiting |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan… | Von Hippel-Lindau Disease | Recruiting |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | Advanced Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid… | Medullary Thyroid Cancer | Active, Not Recruiting |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd… | Cancer | Active, Not Recruiting |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for… | Carcinoma, Renal Cell | Active, Not Recruiting |
| NCT05092958 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy… | Advanced Bladder Urothelial Carcinoma | Active, Not Recruiting |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With… | Clear Cell Renal Cell Carcinoma | Active, Not Recruiting |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… | Cancer | Not Yet Recruiting |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid… | Functioning Pancreatic Neuroendocrine Tumor | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With… | High Grade Osteosarcoma | Recruiting |
| Phase 2 | |||
| NCT05613413 | A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With… | Metastatic Squamous Non-Small Cell Lung Carcinoma | Recruiting |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | Castration-resistant Prostate Cancer | Recruiting |
| NCT07077161 | Cabozantinib Dose Skipping as an Alternative to Dose Reductions | Renal Cell Carcinoma (RCC) | Recruiting |
| NCT06006013 | Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally… | Locally Advanced Adrenal Cortex Carcinoma | Recruiting |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated… | Brain Metastases | Recruiting |
| NCT05019703 | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With… | Locally Advanced Osteosarcoma | Recruiting |
| NCT04116541 | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular… | Malignant Solid Tumor | Recruiting |
| NCT05361720 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney… | Advanced Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular… | Hepatocellular Carcinoma | Recruiting |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the… | Metastatic Renal Cell Carcinoma | Recruiting |
| NCT05425004 | Cabozantinib for Patients With Recurrent or Progressive Meningioma | Meningioma | Recruiting |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug… | Metastatic Nasopharyngeal Carcinoma | Recruiting |